tiprankstipranks
Advertisement
Advertisement

ADCT Stock Latest News

ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
The FlyADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
8d ago
ADCT
ADC Therapeutics price target lowered to $5 from $8 at Stephens
PremiumThe Fly
ADC Therapeutics price target lowered to $5 from $8 at Stephens
12d ago
ADCT
ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
12d ago
ADCT
ADC Therapeutics announces positive ZYNLONTA Phase 3 results
PremiumCompany Announcements
ADC Therapeutics announces positive ZYNLONTA Phase 3 results
13d ago
8K
ADCT
ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL
PremiumThe Fly
ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL
13d ago
ADCT
ADC Therapeutics Shareholders Back Governance and Capital Changes
PremiumCompany AnnouncementsADC Therapeutics Shareholders Back Governance and Capital Changes
14d ago
8K
ADCT
Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8
Premium
Ratings
Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8
1M ago
ADCT
ADC Therapeutics Balances Solid Quarter With Trial Risk
Premium
Company Announcements
ADC Therapeutics Balances Solid Quarter With Trial Risk
1M ago
ADCT
ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year
PremiumThe Fly
ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year
1M ago
ADCT
ADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
ADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet
2M ago
ADCT
ADC Therapeutics Earnings Call: Trials, Cash And Risks
PremiumCompany Announcements
ADC Therapeutics Earnings Call: Trials, Cash And Risks
2M ago
ADCT
ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating
PremiumRatings
ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating
3M ago
ADCT
ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright
PremiumThe FlyADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright
3M ago
ADCT
ADC Therapeutics files to sell 9.83M common shares for holders
Premium
The Fly
ADC Therapeutics files to sell 9.83M common shares for holders
3M ago
ADCT
ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)
Premium
The Fly
ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)
3M ago
ADCT
ADC Therapeutics sees cash runway at least into 2028
PremiumThe Fly
ADC Therapeutics sees cash runway at least into 2028
3M ago
ADCT
ADC Therapeutics Ltd (ADCT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
ADC Therapeutics Ltd (ADCT) Q4 Earnings Cheat Sheet
3M ago
ADCT
ADC Therapeutics Amends Royalty Deal, Issues New Warrants
PremiumCompany Announcements
ADC Therapeutics Amends Royalty Deal, Issues New Warrants
4M ago
8K
ADCT
ADC Therapeutics announces amended HealthCare Royalty financing agreement
PremiumThe Fly
ADC Therapeutics announces amended HealthCare Royalty financing agreement
4M ago
ADCT
ADC Therapeutics participates in a conference call with Cantor
PremiumThe FlyADC Therapeutics participates in a conference call with Cantor
4M ago
ADCT
ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy
Premium
Company Announcements
ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy
5M ago
8K
ADCT
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook
Premium
Company Announcements
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook
5M ago
8K
ADCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >